The Phase 3 study will assess atacicept vs. placebo on the impact of renal (kidney) function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period.
To Learn More Contact:
Vera Therapeutics by phone at 650-770-0077 or email at firstname.lastname@example.org.
ClinicalTrials.gov identifier (NCT number): NCT05609812